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Evidence suggests that probiotic bacteria modulate both innate and adaptive immunity in the host, and in some situations can result
in reduced severity of common illnesses, such as acute rotavirus infection and respiratory infections. Responses to vaccination are
increasingly being used to provide high quality information on the immunomodulatory effects of dietary components in humans. The
present review focuses on the effect of probiotic administration upon vaccination response. The majority of studies investigating the
impact of probiotics on responses to vaccination have been conducted in healthy adults, and at best they show modest effects of
probiotics on serum or salivary IgA titres. Studies in infants and in elderly subjects are very limited, and it is too early to draw any firm
conclusions regarding the potential for probiotics to act as adjuvants in vaccination. Although some studies are comparable in terms of
duration of the intervention, age and characteristics of the subjects, most differ in terms of the probiotic selected. Further well
designed, randomized, placebo-controlled studies are needed to understand fully the immunomodulatory properties of probiotics,
whether the effects exerted are strain-dependent and age-dependent and their clinical relevance in enhancing immune protection
following vaccination.
Introduction
Evidence suggests that probiotic bacteria reduce the risk,
and in some cases duration or severity, of infections [1]. In
infants, a number of studies have demonstrated that pro-
biotics reduce the clinical symptoms of diarrhoeal disease,
particularly in acute rotavirus infection [2–6]. Most studies
have shown that lactobacilli and bifidobacteria reduce the
risk of antibiotic-associated diarrhoea, but data relating to
duration and severity are inconsistent, perhaps due to
some influence of the condition that the patient was being
treated for [1]. Consumption of some probiotic strains may
reduce incidence and/or severity of respiratory infections
in children [7–9], adults [10] and in the elderly [11],
although evidence is limited and studies investigating pre-
vention of common respiratory illnesses have produced
mixed results [1]. A recent systematic review identified
14randomized controlled trials (RCTs) investigating the
effects of probiotics for the prevention of upper or lower
respiratory infections [12].The review concluded that 10 of
these RCTs demonstrated no evidence of beneficial effects
of probiotics on the incidence of respiratory disease, five
out of six providing relevant data demonstrated a reduc-
tion in symptom severity, and three out of nine reported a
shorter clinical course of infection in the probiotic groups
[12].
Response to vaccination is increasingly being used as a
surrogate for the response to infection and can therefore
provide information on the immunomodulatory effects of
dietary components, including probiotics, in humans [13].
Vaccine efficacy can be assessed by levels of vaccine-
specific antibodies in the serum following vaccination,
which directly correlate with protection and are described
as a ‘gold-standard’ for determining the influence of probi-
otics on immune responses [14]. This review discusses the
theoretical basis for modulation of immune response to
vaccination by probiotics, and describes published studies
investigating the impact of concomitant probiotic admin-
istration on the response to vaccination in infants, adults
and elderly individuals.
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Theoretical basis for modulation of
immune response to vaccination by
probiotics
Probiotics may influence immune function by direct and
indirect actions. Direct effects include changes to the gut
microbiota and alteration of the profile of pathogen-
associated molecular patterns (PAMPs) presented to the
gut associated lymphoid tissue. Indirect effects could arise
from microbial products such as short chain fatty acids
[15]. Evidence from animal models indicates that the resi-
dent gut microbiota shapes anti-viral defences and modu-
lates the outcome of viral infections, with germ free mice
more susceptible to a number of infections, including influ-
enza [16]. Experiments with specific pathogen-free (SPF)
mice treated with antibiotics support this. Antibiotic-
treated SPF mice given a sub lethal dose of PR8 virus had
impaired generation of virus specific antibody, cluster of
differentiation 4+ (CD4+) and CD8+ T cell responses and
delayed viral clearance [16].Treatment with antibiotics also
reduced migration of respiratory dendritic cells from the
lung to the draining lymph node during influenza infec-
tion and,as a result, there was a reduction in the priming of
naïve antigen specific CD8+ T cells [17].
Animal studies using antibiotics have identified specific
classes of bacteria involved in maintaining immunity
against viral infection. For example, neomycin almost
completely eliminates Lactobacillus spp. and results in im-
pairment of influenza-specific CD8+ T cell responses,
suggesting that neomycin sensitive bacteria in the gut
support the immune response to influenza infection [16].
Gut microbes are also suggested to support immune
responses against viral infections through inflammasome-
mediated cytokine release. Antibiotic-treated mice have
reduced levels of interleukin-1b (IL-1b) secretion in the
lung during influenza infection, suggesting that gut-
resident bacteria support cytokine production [16]. It has
been speculated that gut microbes release low concentra-
tions of pattern recognition receptor (PRR) ligands, which
provide signals for inflammasome-mediated cytokine
release (for example, in the lung during influenza infec-
tion).These in turn regulate the activity of respiratory den-
dritic cells during activation of adaptive immunity against
the virus [16]. Evidence that gut-resident bacteria play a
role in shaping immune defences form the basis for the
hypothesis that probiotics may modulate responses to
infection or vaccination. However, the mechanisms by
which probiotics modulate the immune system, particu-
larly in the context of vaccination, are not clear. A recent
animal study demonstrated that the probiotic, Lactobacil-
lus gasseri, led to diversification of B cell populations in the
lamina propria of the murine colon in vivo. This organism
was proposed as a vaccine vector for oral immunization
against mucosal pathogens [18]. Another study demon-
strated that Lactobacillus paracasei subsp. paracasei NTU
101 fed daily to mice for 3 to 9 weeks induced stronger
interactions between CD4+ T cells and dendritic cells and
enhanced proliferation of CD4+ T cells and B cells [19].
Thus, there is compelling evidence that resident bacte-
ria in the gastro-intestinal tract influence the immune
response to viral infections. However specific data relating
to vaccination responses is lacking. The following sections
review published studies investigating the impact of con-
comitant probiotic administration on the response to vac-
cination in humans.
Studies in infants
Oral vaccines
Two studies investigated the effects of probiotics on
responses to oral vaccines in infants. One study examined
the influence of Lactobacillus casei strain GG (currently
known as Lactobacillus rhamnosus GG or LGG) on the oral
rotavirus vaccine [20],and the other examined the effect of
the Bifidobacterium breve strain in Yakult (BBG-01) on the
oral cholera vaccine [21] (see Table 1). In the first study,
2–5-month-old infants were given LGG or a placebo imme-
diately before receiving the oral rotavirus vaccine (D x RRV)
and for the subsequent 5 days [20]. LGG significantly
increased the number of rotavirus-specific Immunoglobu-
lin M (IgM) antibody secreting cells 8 days after vaccina-
tion, and a trend for higher rotavirus-specific IgA antibody
titres was also observed in the probiotic group compared
with the placebo group (P = 0.05).
In contrast, there was no effect of Bifidobacterium breve
strainYakult (BBG-01),given for 4weeks,on the response to
oral cholera vaccine in 2–5-year-old Bangladeshi children
[21].There were significantly lower proportion of respond-
ers in the probiotic group for some viral-specific IgA anti-
bodies compared with the placebo group. This was
particularly evident in the younger infants.
Parenteral vaccines
Five studies investigated the effects of probiotics on
responses to parenteral vaccines in infants (Table 1).
Kukkonen et al. [22], investigated the effect of a mixture of
four probiotics combined with the prebiotic galacto-
oligosaccharide (GOS) on antibody responses to diphthe-
ria, tetanus and Haemophilus influenza type b (Hib)
vaccination in allergy-prone infants. Pregnant mothers
received the probiotics during their last month of preg-
nancy, and the same mixture was given in combination
with GOS syrup to their newborns for 6 months. Vaccines
were administered at 3,4 and 5 months and antibody titres
were measured at 6 months. A protective Hib-specific IgG
antibody response (>1 mgml-1) occurred more frequently
in the probiotic group (16 of 29 infants) comparedwith the
placebo group (6 of 25 infants), but there were no signifi-
cant differences in vaccine-specific antibody titres
between groups.
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In a similar study, the probiotic Lactobacillus acidophilus
LAVR1-A1 (Probiomics) was fed to allergy-prone infants for
the first 6 months of life and the response to tetanus
vaccine was assessed at 2, 4 and 6 months [23]. The probi-
otic decreased the IL-10 response to tetanus toxoid antigen
at 6 months compared with the placebo group and
reduced IL-5 and transforming growth factor-b (TGF-b)
release by peripheral bloodmononuclear cells (PBMCs) fol-
lowing stimulation with Staphylococcal enterotoxin B
(SEB).However,antibody responses to the vaccinewere not
reported. In the study by West et al. [24], 4-month-old
infants were provided with a cereal containing Lactobacil-
lus paracasei ssp. paracasei strain F19 (LF19), or the same
cereal without probiotic, daily for 9 months. The infants
were immunizedwith DTaP (diphtheria, tetanus toxoid and
acellular pertussis), polio and Hib vaccines at 3, 5.5 and
Table 1
Studies investigating the effects of probioics on vaccine responses in infants
Probiotic(s) Vaccine(s) Study design Outcomes Reference
Lactobacillus casei strain GG
(Lactobacillus rhamnosus GG or
LGG) 5 ¥ 1010 (cfu) twice daily
Oral DxRRV rhesus-human
reassortant rotavirus
vaccine
Infants (2–5 months) given
probiotic (n = 29) or placebo
(n = 28) as a powder
reconstituted in 5 ml water
after vaccination and for next 5
days
• Increase in IgM antibody secreting cells
in LGG vs. placebo group (P = 0.02)
• Trend for higher IgA in LGG group
(P = 0.05)
Isolauri et al. (1995)
[20]
Bifidobacterium breve (BBG-01)
4 ¥ 109 cfu day-1
Oral cholera vaccine
Dukoral®
Infants (2–5 years) given probiotic
(n = 64) or placebo (n = 60) for
4 weeks, vaccination on days
21 and 35
• Significantly lower proportion of
responders in the probiotic group for
some viral-specific IgA antibodies
compared with the placebo group
(P = 0.016 for viral CTB specific IgA)
Matsuda et al.
(2011) [21]
Lactobacillus rhamnosus GG (LGG)
(ATCC 53103) 5 ¥ 109 cfu,
Lactobacillus rhamnosus (LC705)
5 ¥ 109 cfu, Bifidobacterium
breve (Bbi99) 2 ¥ 108 cfu,
Propionibacterium freudenreichii
ssp. Shermanii JS 2 ¥ 109
cfu day-1 (twice daily for
pregnant mothers)
Parenteral diphtheria, tetanus
and whole cell pertussis
(DTwP), Haemophilus
influenzae type b (Hib)
vaccines
Pregnant mothers given probiotics
or placebo capsules for last
month of pregnancy; same
mixture as a powder given in
combination with prebiotic
GOS sugar syrup to newborns
for 6 months (n = 47 probiotic,
n = 40 placebo group). DTwP
vaccines given at 3, 4 and
5 months, Hib vaccine at
4 months
• Higher frequency of Hib-specific IgG
antibody response in the probiotic (16 of
29 infants) vs. placebo (6 of 25 infants,
P = 0.023)
• Trend for higher Hib-specific IgG
antibody titres (P < 0.064)
• Diphtheria- and tetanus-specific IgG the
titres comparable between groups
Kukkonen et al.
(2006) [22]
Lactobacillus acidophilus LAVRI-A1
3 ¥ 109 cfu day-1
Parenteral tetanus vaccine Newborn infants given probiotic
(n = 58) or placebo (n = 60) for
6 months as a powder;
vaccinations at 2, 4 and
6 months
• Lower IL-10 responses to tetanus
antigen in probiotic vs. placebo group
(P = 0.03)
Taylor et al. (2006)
[23]
Lactobacillus paracasei ssp.
paracasei strain F19 1 ¥ 109
cfu day-1
Parenteral diphtheria, tetanus
toxoid and acellular
pertussis (DTaP), polio and
Hib vaccines
Infants (4 months) given cereals
with probiotic (n = 89) or
placebo (n = 90) for 9 months;
vaccines administered at 3, 5.5
and 12 months
• No significant differences in vaccine
specific antibody titres between groups
• When adjusted for breastfeeding
duration the probiotic enhanced
anti-diphtheria antibody titres in infants
breastfed for < 6 months (P = 0.024)
• A similar trend for tetanus antigen
(P = 0.035) but no difference for Hib
West et al. (2008)
[24]
Bifidobacterium longum BL999 1 ¥
107 cfu, Lactobacillus rhamnosus
LPR 2 ¥ 107 cfu day-1
Schedule A: Monovalent
hepatitis B (HepB) vaccine
at dose 1 and 2, DTaP
vaccine containing HepB
component at dose 3;
Schedule B: monovalent
HepB vaccine for all doses
Newborn infants given probiotic
or placebo for 6 months;
vaccinations according to
schedule A (probiotic n = 29,
placebo n = 28) or B (probiotic
n = 77, placebo n = 68) at 0, 1
and 6 months
• Trend for probiotic supplementation to
increase HepB virus surface antibody
(HBsAb) responses in infants on
schedule A (P = 0.069)
• No effect of probiotic on antibody titres
in infants on schedule B
Soh et al. (2010)
[25]
Lactobacillus acidophilus strain
ATCC4356, Bifidobacterium
bifidum DSMZ20082,
Bifidobacterium longum
ATCC157078, Bifidobacterium
infantis ATCC15697 3 ¥ 109
cfu day-1 (Altman Probiotic Kid
Powder)
Parenteral mumps, measles,
rubella and varicella
(MMRV) vaccine
Infants (8–10 months) given the
probiotics (n = 25) or placebo
(n = 22) as a powder for
5 months, starting 2 months
prior to vaccination
• No difference in vaccine-specific IgG
antibody titres between probiotic and
placebo groups
• When combining all the antibody
results, more infants reached protective
IgG antibody titres 3 months
post-vaccination in probiotic vs. placebo
group (P = 0.052)
Youngster et al.
(2011) [26]
cfu, colony-forming units.
Probiotics and vaccination response
Br J Clin Pharmacol / 75:3 / 665
12 months.There was no significant effect of the probiotic
on antibody titres to Hib, diphtheria and tetanus antigens
measured before and after the second and third doses of
vaccines. However, adjustment for breastfeeding duration
suggested that the probiotic enhanced anti-diphtheria
antibody titres in infants breastfed for less than 6 months.A
similar effect was observed for tetanus antigen, but there
was no effect of LF19 on Hib vaccination.
Soh et al. [25] examined the response to hepatitis B
(HepB) vaccination in allergy-prone infants fed formula
supplemented with Bifidobacterium longum BL999 and
Lactobacillus rhamnosus LPR or a control formula without
probiotics for the first 6 months of life. All infants received
a monovalent HepB vaccine at birth and 1 month of age,
and at 6 months they received either the monovalent
HepB vaccine or a hexavalent diphtheria-tetanus-acellular
pertussis (DTaP) combination vaccine containing a HepB
component. There was a trend for the probiotic mix to
increase HepB virus surface antibody (HBsAb) responses in
those infants receiving HepB + DTaP, but this was not sta-
tistically significant,and therewas no effect of probiotics in
infants receiving the monovalent HepB.
Finally, in the study by Youngster et al. [26], 8–10-
month-old infants were provided with a probiotic formu-
lation comprising Lactobacillus acidophilus ATCC4356,
Bifidobacterium bifidum DSMZ20082, Bifidobacterium
longum ATCC157078 and Bifidobacterium infantis
ATCC15697 (Altman Probiotic Kid Powder) for 5 months in
total, beginning 2 months prior to vaccination against
mumps, measles, rubella and varicella (MMRV) [26]. While
there was no significant difference in protective antibody
titres to each individual vaccine component,when all anti-
body results were combined, there was a trend towards a
greater percentage of infants reaching protective IgG anti-
body titres 3 months post-vaccination in the probiotic
group [26].
Summary of studies in infants
There are a limited number of studies investigating the
influence of probiotics on vaccination in infants and the
effects are not clear. At best, there are trends towards
better responses to vaccination in some of the studies, but
effects are clearly limited.Although some studies are com-
parable in terms of duration of the intervention, age and
characteristics of the infants, the probiotics administered
are different in every case. Further research is required to
compare the effects of different probiotics within a stand-
ardized study design.
Studies in adults
Seven studies have investigated the influence of probiotics
on response to vaccination in adults, four of these employ-
ing oral vaccines, two employing parenteral vaccines, and
one a nasally administered vaccine (Table 2).
Oral vaccines
Fermented milk containing Lactobacillus acidophilus La1
and Bifidobacterium Bb12 consumed for 3 weeks signifi-
cantly increased the vaccine-specific serum IgA titres to an
attenuated Salmonella typhi Ty21a oral vaccine given on
days 7, 9 and 11 [27]. In a separate study, LGG taken for
7 days tended to increase vaccine-specific IgA antibodies
to the Salmonella typhi Ty21a oral vaccine administered on
days 1, 3 and 5 [28]. However, there was no effect of Lacto-
coccus lactis, and no effect of either probiotic on the
numbers of vaccine specific IgA, IgG or IgM antibody
secreting cells 7 days post-vaccination [28]. Vaccine-
specific IgA titre to an oral poliovirus vaccinewas increased
by LGG and Lactobacillus paracasei ssp. paracasei (CRL431)
during a 5 week intervention, with the live attenuated
poliomyelitis virus vaccine being administered on day 8
[29]. Those receiving the probiotics had a significantly
greater increase in neutralizing antibodies compared with
a placebo group. There was also a minor effect on poliovi-
rus serotype-1-specific IgG and on serotype-2-and
-3-specific IgM antibody titres [29]. Strain specific effects of
probiotics on response to an oral cholera vaccine were
explored by Paineau et al. [30]. Healthy adult volunteers
were assigned to one of seven probiotics (members of the
genera Lactobacillus and Bifidobacterium) or placebo for 21
days and received the oral cholera vaccine on days 7 and
14. Bifidobacterium lactis Bi-04 and Lactobacillus acido-
philus La-14 significantly increased vaccine-specific serum
IgG antibody levels on day 21,and therewas a similar trend
for Bifidobacterium lactis Bi-07 and Lactobaacillus
plantarum Lp-115. However, there were no significant
effects of probiotics on vaccine-specific serum IgA or IgM
antibodies [30].
Parenteral vaccines
Three studies have examined the potential adjuvant prop-
erties of probiotics given in conjunction with parenteral or
nasally administered influenza vaccines (Table 2). In the
first study, Lactobacillus fermentum CECT5716, taken for 4
weeks, significantly increased titres of influenza virus-
specific plasma IgA (but not IgM or IgG) to the inactivated
trivalent influenza vaccine for the vaccine campaign of
2004/2005, administered 2 weeks into the intervention
[31]. Additionally, the incidence of influenza-like illnesses
for 5 months post-vaccination were lower in the probiotic
group comparedwith the control group [31]. In the second
study,both Bifidobacterium animalis ssp. lactis (BB-12®) and
Lactobacillus paracasei ssp. paracasei (L. casei 431®) taken
for 6 weeks increased influenza vaccine-specific serum IgG
and vaccine-specific salivary sIgA titres after vaccination at
2 weeks in the 2008/2009 campaign [32]. There was no
effect of either probiotic on vaccine-specific serum IgA or
IgMon plasma cytokine concentrations or on parameters
of innate immunity [32]. Finally, LGG taken for 28 days
immediately after receiving a nasally administered triva-
lent live attenuated influenza vaccine from the campaign
C. Maidens et al.
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of 2007/2008 significantly increased seroprotection (hae-
magglutinin inhibition [HAI] antibody titre = 40) to the
H3N2 virus strain, but not to the H1N1 or B strain at day 28
[33]. However, at day 56 the rates of seroconversion (at
least a four-fold rise in HAI antibody titre) were not signifi-
cantly different.
Summary of studies in adults
Overall, some studies in adults demonstrate an increase in
vaccine-specific serum IgA concentrations, but this is not
entirely consistent. Effects on other Ig subclasses and on
seroprotection/seroconversion are unclear.
Studies in elderly subjects
Three studies examined the effect of probiotics on the
response to parenteral influenza vaccines in elderly sub-
jects (Table 3). This is a particularly important group for
consideration because of the impact of immunosenes-
Table 2
Studies investigating the effects of probioics on vaccine responses in adults
Probiotic(s) Vaccine(s) Study design Outcomes Reference
Streptococcus thermophilus,
Lactobacillus acidophilus La1
and Bifidobacterium Bb12
5 ¥ 109 cfu day-1
Oral attenuated Salmonella typhi
Ty21a vaccine
Healthy adults given probiotic
yoghurt (n = 16) or no
intervention (n = 14) for 3
weeks; vaccination on days 7,
9 and 11
• Greater increase in vaccine-specific
serum IgA antibody titre in probiotic vs.
control group (P = 0.04)
Link-Amster et al.
(1994) [27]
Lactobacillus GG (LGG) 4 ¥ 1010
cfu day-1 or Lactococcus
lactis (L.lactis) 3.4 ¥ 1010
cfu day-1
Oral attenuated Salmonella typhi
Ty21a vaccine
Healthy adult volunteers receiving
LGG (n = 10), L. lactis (n = 10)
or placebo (n = 9) for 7 days;
vaccination on days 1, 3 and 5
• No significant difference in
vaccine-specific IgA, IgG or IgM
antibody secreting cells between groups
• Trend for higher vaccine-specific IgA
antibody in LGG group
Fang et al (2000)
[28]
Lactobacillus rhamnosus GG
(LGG)
Lactobacillus paracasei ssp.
paracasei strain CRL431
(CRL431) 1 ¥ 1010 cfu day-1
Oral attenuated poliomyelitis virus
types 1, 2 and 3 vaccine
Healthy males given yogurt with
LGG (n = 21), CRL431 (n = 21)
or no probiotic (n = 22) for
5 weeks; vaccination on day 8
• Significantly greater increase in
neutralizing antibodies and enhanced
poliovirus-specific IgA titre in probiotic
groups vs. placebo group (P < 0.036)
• Probiotics had a minor effect on
poliovirus serotype-1-specific IgG and on
serotype-2- and -3-specific IgM
antibody titres
de Vrese et al. (2005)
[29]
Lactobacillus strains:
L. acidophilus La-14,
L. acidophilus NCFM®,
L. plantarum Lp-115,
L. paracasei Lpc-37,
L. salivarius Ls-33,
Bifidobacterium strains:
B. lactis Bl-04, B. lactis Bi-07
1 ¥ 1010 cfu twice daily
Oral cholera vaccine Dukoral® Healthy adults assigned to one of
seven probiotics (n = 9 for
each) or placebo (n = 20) for
21 days; vaccination on days 7
and 14
• Significantly higher vaccine-specific
serum IgG antibody levels on day 21 in
subjects given probiotics B. lactis Bl-04
and L. acidophilus La-14 vs. control
group (P = 0.01)
• Similar trend for B. lactis Bi-07 and
L. plantarum Lp-115 supplementation
Paineau et al. (2008)
[30]
Lactobacillus fermentum
(CECT5716) 1 ¥ 1010 cfu day-1
Parenteral inactivated trivalent
influenza vaccine for the
campaign of 2004/2005
Healthy adults given probiotic
(n = 25) or placebo (n = 25) for
4 weeks; vaccination on day 14
• Probiotic increased vaccine-specific IgA
antibodies post-vaccination (P < 0.05)
• Incidence of influenza-like illnesses for 5
months post-vaccination lower in the
probiotic vs. placebo group (P < 0.05 for
last month)
Olivares et al. (2007)
[31]
Bifidobacterium animalis ssp.
lactis (BB-12®) or
Lactobacillus paracasei ssp.
paracasei (L.casei 431®)
1 ¥ 109 day-1
Parenteral attenuated trivalent
influenza vaccine for the
campaign of 2008/2009
Healthy adults given probiotic
(n = 53 for BB-12®, n = 56 for
L.casei 431®) or placebo
(n = 102) for 6 weeks;
vaccination at week 2
• Significantly greater increase in
vaccine-specific IgG antibody titre in
probiotic groups vs. placebo (P < 0.001
for IgG1 and IgG3)
• Significantly greater mean-fold increases
for vaccine-specific secretory IgA
antibody in saliva in BB-12® group
(P = 0.035) and L.casei 431® group
(P = 0.017) vs. placebo group
Rizzardini et al.
(2011) [32]
Lactobacillus GG (LGG) 1 ¥ 1010
cfu and 295 mg prebiotic
inulin twice daily
Nasally administered attenuated
trivalent influenza vaccine for
the campaign of 2007/2008
Healthy adults given probiotic
(n = 21) or placebo (n = 21) for
28 days after vaccination
• LGG significantly increased
seroprotection rate to the H3N2 strain at
day 28 (P = 0.048), but not to the H1N1
or B strain
• No effect on seroconversion rates at day
56
Davidson et al (2011)
[33]
cfu, colony-forming units.
Probiotics and vaccination response
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cence on response to vaccination, and the consequences
of respiratory infections in older people [34]. Bunout et al.
[35], examined the effects of a complete nutritional
formula containing a range of nutrients and vitamins plus
the probiotic Lactobacillus paracasei (NCC 2461) and the
prebiotic fructo-oligosaccharide for 6 months on the
response to influenza and pneumococcal vaccines (given
at 4 months) in free-living Chilean subjects over 70-years-
old.At 12 months there was a significantly lower incidence
of infection, in particular, respiratory infection, in the treat-
ment group compared with the control group, but there
was no effect on antibody responses to either vaccine [35].
Boge et al. [36], conducted an intervention trial of a probi-
otic drink containing Lactobacillus paracasei ssp. paracasei
(Actimel®) on the response to influenza vaccination in
healthy elderly volunteers (>70 years). This trial was con-
ducted in two phases: a pilot study in 2005–2006
(probiotic/placebo consumed for 7 weeks), followed by a
confirmatory study in 2006–2007 (probiotic/placebo con-
sumed for 13 weeks), with the inactivated influenza virus
vaccine being administered during the fourth week of
intervention.H1N1 was the only vaccine strain common to
both phases of the study, with the H3N2 and B strains
being different between vaccination seasons. In both
phases of the trial, the probiotic group exhibited higher
virus-specific antibody titres post-vaccination compared
with the control group, although these differences were
only statistically significant within the confirmatory phase
[36]. The intensity of the probiotic effect was vaccine
subtype-dependent, with the most pronounced enhance-
ment for the influenza virus H3N2 strain in the pilot and
the B strain in the confirmatory study.Seroconversion rates
within the probiotic group in the confirmatory phase were
significantly higher for the B strain at 3, 6 and 9 weeks
post-vaccination compared with the placebo group
(P = 0.02), but there was no effect of the probiotic on sero-
conversion for the H1N1 or H3N2 strains [36]. It is perhaps
pertinent to note that the B strain is known to show major
human variability,and the effects on this subtype therefore
need to be interpreted with caution.The third study is not
included in Table 3 because of an unusual study design,
which makes the data very difficult to interpret [37]. In this
small study, 27 elderly subjects consumed a test food con-
taining Bifidobacterium longum BB536 for 5 weeks,with an
influenza vaccination (2004/2005 campaign) being given
at 3 weeks.At 5 weeks, the subjects were then randomized
to either continue on the probiotic, or to consume a
placebo for a further 14 weeks. The randomization was
stratified for gender and H3N2 titres, but not for overall
protection, so that the proportion of subjects with effec-
tive titre was 53.8% in the BB536 group and 28.6% in the
placebo group [37]. Although the paper reports signifi-
cantly lower incidence of influenza and fever in the probi-
otic group, the subject numbers are extremely small, and
these data should probably be disregarded.
Summary of studies in elderly subjects
Studies are very limited, and it is too early to draw any
conclusions regarding the potential influence of probiotics
on the response to influenza vaccination in elderly sub-
jects. More research is required.
Conclusion
The majority of studies investigating the impact of probi-
otics on responses to vaccination have been conducted in
healthy adults, and at best they show modest effects of
probiotics on serum or salivary IgA titres. Studies in infants
and in elderly subjects are very limited,and it is too early to
Table 3
Studies investigating the effects of probioics on vaccine responses in elderly subjects
Probiotic(s) used Vaccine(s) used Study design Outcomes Reference
Lactobacills paracasei (NCC
2461) 1 ¥ 109 cfu and 6 g
prebiotic fructo-
oligosaccharide as part of
a daily nutritional formula
Parenteral trivalent influenza
vaccine and pneumococcal
vaccine containing 23 serotypes
Elderly subjects (70 years) given either
nutritional formula containing a
range of nutrients and vitamins plus
the probiotic NCC 2461 and prebiotic
for 6 months or no supplement;
vaccination after 4 months
• No effect on antibody response to
vaccines
• Significantly lower incidence of
infection after 12 months, in
particular respiratory illnesses, in
treatment group vs. controls
(P = 0.034)
Bunout et al. (2004)
[35]
Lactobacillus paracasei ssp.
paracasei (Actimel®)
1010cfu/100 g bottle twice
daily
Parenteral inactivated trivalent
influenza virus vaccine
(2005–2006 campaign vaccine
for pilot study and 2006–2007
for confirmatory study)
Pilot study: probiotic (n = 44) or placebo
(n = 42) consumed for 7 weeks
Confirmatory study: probiotic (n = 113)
or placebo (n = 109) consumed for
13 weeks. Vaccination after 4 weeks
• Trend for higher virus-specific
antibody titres in probiotic vs. control
group
• Significantly greater seroconversion
rate for B strain in main study at 3, 6
and 9 weeks post-vaccination in
probiotic vs. placebo group (P = 0.02)
Boge et al. (2009)
[36]
cfu, colony-forming units.
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draw any firm conclusions regarding the potential for pro-
biotics to act as adjuvants in vaccination. There is strong
evidence that probiotics reduce the incidence and dura-
tion of diarrhoeal infection among infants and adults [1].
Further studies of the effect of probiotics on the response
to rotavirus and cholera vaccination in infants and cholera
or Salmonella vaccination in adults would therefore be of
interest.
Evidence suggests that probiotics can reduce the dura-
tion,but not the incidence,of common respiratory illnesses
[1]. Two studies which monitored the incidence and dura-
tion of cold and flu-like symptoms following Influenza
vaccination have indeed identified a lower incidence of
infections among those receiving probiotic treatment [31,
35]. Influenza vaccination provides a particularly useful
tool because it is used in routine clinical practice in elderly
people, in whom seroprotection and seroconversion rates
are low and correlate with poor protection. Unfortunately,
very few of the studies published to date have reported
rates of seroprotection and seroconversion. This informa-
tion is critical in evaluating the potential clinical benefits
of probiotics as adjuvants for vaccination. Further well
designed, randomized, placebo-controlled studies are
needed to understand fully the immunomodulatory prop-
erties of probiotics, whether the effects exerted are strain
and age-dependent,and their clinical relevance in enhanc-
ing protection following vaccination.
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